Ticker > Company >

Bliss GVS Pharma share price

Bliss GVS Pharma Ltd.

NSE: BLISSGVS BSE: 506197 SECTOR: Pharmaceuticals & Drugs  72.43 K   233   25

184.05
+28.40 (18.25%)
BSE: 30 Jul 04:01 PM

Price Summary

Today's High

₹ 186.75

Today's Low

₹ 166.05

52 Week High

₹ 184.95

52 Week Low

₹ 105.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1943.04 Cr.

Enterprise Value

1822.94 Cr.

No. of Shares

10.56 Cr.

P/E

27.52

P/B

1.81

Face Value

₹ 1

Div. Yield

0.27 %

Book Value (TTM)

₹  101.68

CASH

171.11 Cr.

DEBT

51.01 Cr.

Promoter Holding

35.44 %

EPS (TTM)

₹  6.69

Sales Growth

10.2%

ROE

6.78 %

ROCE

9.31%

Profit Growth

36.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Bliss GVS Pharma Ltd.

Alain Gvither Lonart Rectol PARAFEN Vomitin Slipizem tacy Imazole Ecozole Vagikit Lofnac Comit Zinvite Clomain Alvite FUNBACT SOAP TODAY Instant Head Sanitizer SOFTNESS Mosquito Repellant Cream VAGID Dusting powder ALLSOFT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.2%
3 Year1.59%
5 Year8.59%

Profit Growth

1 Year36.18%
3 Year-9.38%
5 Year-5.67%

ROE%

1 Year6.78%
3 Year7.25%
5 Year8.58%

ROCE %

1 Year9.31%
3 Year9.85%
5 Year11.25%

Debt/Equity

0.0485

Price to Cash Flow

19.99

Interest Cover Ratio

15.3035

CFO/PAT (5 Yr. Avg.)

1.10661150915657

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.44 0.00
Mar 2025 35.29 0.00
Dec 2024 35.10 0.00
Sep 2024 34.82 0.00
Jun 2024 34.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 15.3035.
  • Company’s PEG ratio is 0.779599997440286.
  • Company has a healthy liquidity position with current ratio of 6.1635.
  • The company has a good cash flow management; CFO/PAT stands at 1.10661150915657.

 Limitations

  • The company has shown a poor profit growth of -9.37521298963219% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.5904151519226% for the Past 3 years.
  • Company has a poor ROE of 7.25063333333333% over the past 3 years.
  • Company has high debtor days of 226.4167.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 148.96 182.65 179.59 156 163.36
Total Expenditure 122.22 157.27 153.86 142.27 130.6
Operating Profit 26.74 25.38 25.73 13.73 32.77
Other Income 6.84 8.35 11.66 9.36 10.59
Interest 1.17 3.45 0.67 1.3 5.11
Depreciation 6.26 6.4 6.96 7.44 7.69
Exceptional Items 0 0 0 0 0
Profit Before Tax 26.15 23.89 29.77 14.36 30.56
Tax 6.73 6.85 8.72 2.91 9.51
Profit After Tax 19.42 17.04 21.05 11.45 21.05
Adjusted EPS (Rs) 1.85 1.62 2 1.09 2

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 465.51 636.36 598.34 605.46 667.2
Total Expenditure 374.05 527.16 508.18 498.29 575.62
Operating Profit 91.46 109.2 90.16 107.17 91.59
Other Income 19.41 32.63 50.77 33.5 36.22
Interest 5.92 4.32 10.06 5.81 6.58
Depreciation 13.76 13.85 15.17 23.52 27.05
Exceptional Items 0 2.75 0 -41.09 0
Profit Before Tax 91.19 126.4 115.69 70.26 94.17
Tax 23.69 33.74 30.21 19.61 25.2
Net Profit 67.5 92.66 85.48 50.64 68.97
Adjusted EPS (Rs.) 6.54 8.94 8.21 4.84 6.55

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10.31 10.37 10.42 10.47 10.54
Total Reserves 745.33 841.06 926.58 977.97 1048.1
Borrowings 32.49 23.22 40.69 35.1 19.67
Other N/C liabilities 11.38 12.48 8.65 7.73 7.74
Current liabilities 146.11 192.83 153.36 114.89 124.55
Total Liabilities 945.62 1079.96 1139.69 1146.16 1210.6
Assets
Net Block 174.1 224.31 324.82 329.95 367.89
Capital WIP 2.39 22.15 2.8 7.83 20.58
Intangible WIP 0 0 0 0 0
Investments 18.3 18.26 18.26 18.69 18.69
Loans & Advances 11.35 22.44 17.18 14.27 16.24
Other N/C Assets 62.84 1.05 46.99 3.19 19.52
Current Assets 676.64 791.74 729.65 772.23 767.69
Total Assets 945.62 1079.96 1139.69 1146.16 1210.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 91.19 123.66 115.69 111.34 94.17
Adjustment 41.14 35.1 41.42 44.25 56.44
Changes in Assets & Liabilities -42.64 -14.23 -75.58 -44.08 -23.08
Tax Paid -22.72 -30.47 -37.72 -29.34 -30.33
Operating Cash Flow 66.97 114.05 43.81 82.17 97.21
Investing Cash Flow -61.62 -92.28 -12.97 -65.84 -77.73
Financing Cash Flow -11.67 -12.62 -26.05 -20.76 -26.71
Net Cash Flow -6.33 9.14 4.79 -4.43 -7.23

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 34.90 34.82 35.10 35.29 35.44
gagan harsh sharma - - - - 0.19
narsimha shibroor kamath 30.47 30.39 30.69 30.78 30.75
punita sharma 0.02 0.02 0.02 0.02 0.02
ramadas vasudev kamath hu... - - 0.03 - 0.03
shibroor gokuldas kamath 0.01 0.01 0.01 0.01 0.01
shruti vishal rao 2.01 2.01 2.00 2.00 2.00
vibha gagan sharma 2.36 2.35 2.35 2.44 2.44
ramadas vasudev kamath. 0.03 0.03 - 0.03 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 65.10 65.18 64.90 64.71 64.56
arian investment limited 8.96 8.79 8.76 8.58 7.93
arjun gautam ashra . 4.81 4.80 4.79 4.79 4.79
coeus global opportunitie... - 1.77 1.76 1.76 1.76
gautam rasiklal ashra 2.83 2.81 2.83 2.83 2.83
gulbarga trading and inve... 5.57 5.55 5.53 5.53 5.53
investor education and pr... 2.38 2.38 2.37 2.45 2.44
life insurance corporatio... 6.58 6.56 6.55 6.55 6.54
llp 0.04 0.07 0.10 0.22 0.23
aspire emerging fund 1.34 - - - -
polus global fund 1.77 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INFOMERIC
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Bliss GVS Pharma Stock Price Analysis and Quick Research Report. Is Bliss GVS Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Bliss GVS Pharma and its performance over the period of time. Bliss GVS Pharma stock price today is Rs 183.17.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Bliss GVS Pharma cash from the operating activity was Rs 97.2054 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Bliss GVS Pharma has a Debt to Equity ratio of 0.0485 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Bliss GVS Pharma , the EPS growth was 35.3026 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Bliss GVS Pharma has OPM of 13.7267638742299 % which is a bad sign for profitability.
     
  • ROE: Bliss GVS Pharma have a poor ROE of 6.7847 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Bliss GVS Pharma is Rs 183.17. One can use valuation calculators of ticker to know if Bliss GVS Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Bliss GVS Pharma
X